Immutep Dirección

Dirección controles de criterios 2/4

El CEO de Immutep's es Marc Voigt , nombrado en Nov 2012, tiene una permanencia de 11.42 años. compensación anual total es A$1.11M, compuesta por 39.5% salario y 60.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.95% de las acciones de la empresa, por valor de A$3.99M. La antigüedad media del equipo directivo y de la junta directiva es de 6.3 años y 1.9 años, respectivamente.

Información clave

Marc Voigt

Chief Executive Officer (CEO)

AU$1.1m

Compensación total

Porcentaje del salario del CEO	39.5%
Permanencia del CEO	11.5yrs
Participación del CEO	0.9%
Permanencia media de la dirección	6.4yrs
Promedio de permanencia en la Junta Directiva	2yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Marc Voigt en comparación con los beneficios de Immutep?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-AU$41m
Sep 30 2023	n/a	n/a	-AU$40m
Jun 30 2023	AU$1m	AU$440k	-AU$40m
Mar 31 2023	n/a	n/a	-AU$38m
Dec 31 2022	n/a	n/a	-AU$37m
Sep 30 2022	n/a	n/a	-AU$34m
Jun 30 2022	AU$943k	AU$428k	-AU$32m
Mar 31 2022	n/a	n/a	-AU$29m
Dec 31 2021	n/a	n/a	-AU$26m
Sep 30 2021	n/a	n/a	-AU$28m
Jun 30 2021	AU$995k	AU$409k	-AU$30m
Mar 31 2021	n/a	n/a	-AU$29m
Dec 31 2020	n/a	n/a	-AU$27m
Sep 30 2020	n/a	n/a	-AU$20m
Jun 30 2020	AU$926k	AU$411k	-AU$13m
Mar 31 2020	n/a	n/a	-AU$15m
Dec 31 2019	n/a	n/a	-AU$16m
Sep 30 2019	n/a	n/a	-AU$17m
Jun 30 2019	AU$837k	AU$399k	-AU$18m
Mar 31 2019	n/a	n/a	-AU$18m
Dec 31 2018	n/a	n/a	-AU$17m
Sep 30 2018	n/a	n/a	-AU$15m
Jun 30 2018	AU$1m	AU$401k	-AU$13m
Mar 31 2018	n/a	n/a	-AU$12m
Dec 31 2017	n/a	n/a	-AU$10m
Sep 30 2017	n/a	n/a	-AU$9m
Jun 30 2017	AU$668k	AU$329k	-AU$9m

Compensación vs. Mercado: La compensación total ($USD718.56K) de Marc está en línea con el promedio de empresas de tamaño similar en el mercado Australian ($USD625.62K).

Compensación vs. Ingresos: La compensación de Marc ha aumentado mientras la empresa no es rentable.

CEO

Marc Voigt (50 yo)

11.5yrs

Permanencia

AU$1,114,122

Compensación

Mr. Marc Voigt has been the Chief Executive Officer of Immutep Limited (formerly, Prima BioMed Ltd) since July 9, 2014. Mr. Voigt has been an Executive Director of Immutep Limited since July 9, 2014. He se...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Marc Voigt	CEO, MD	11.5yrs	AU$1.11m	0.95% A$ 4.9m
Deanne Miller	COO, General Counsel & Joint Company Secretary	11.6yrs	AU$595.80k	0.27% A$ 1.4m
Frederic Triebel	Chief Scientific Officer & Executive Director	9.4yrs	AU$744.24k	0.74% A$ 3.8m
Christian Mueller	Senior Vice President of Regulatory & Strategy	less than a year	sin datos	sin datos
Florian Vogl	Chief Medical Officer	less than a year	sin datos	sin datos
Indira Naidu	Joint Company Secretary	3.3yrs	sin datos	sin datos

6.4yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de IMM es experimentado (6.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Marc Voigt	CEO, MD	9.8yrs	AU$1.11m	0.95% A$ 4.9m
Frederic Triebel	Chief Scientific Officer & Executive Director	1.7yrs	AU$744.24k	0.74% A$ 3.8m
Russell Howard	Independent Non-Executive Chairman	11yrs	AU$171.99k	0.094% A$ 484.3k
Pete Meyers	Independent Non-Executive Deputy Chairman	10.3yrs	AU$192.28k	0.28% A$ 1.4m
Martine Piccart	Chairman of Clinical Advisory Board	6.9yrs	sin datos	sin datos
Scott Antonia	Member of Clinical Advisory Board	2yrs	sin datos	sin datos
Leisha Emens	Member of Clinical Advisory Board	2yrs	sin datos	sin datos
Elisabeth Boyce	Non-Executive Director	1.1yrs	AU$62.32k	sin datos
Salah-Eddin Al-Batran	Member of Clinical Advisory Board	6.9yrs	sin datos	sin datos
Martin Forster	Member of Clinical Advisory Board	2yrs	sin datos	sin datos
Hans Wildiers	Member of Clinical Advisory Board	2yrs	sin datos	sin datos
Anne Anderson	Non-Executive Director	less than a year	sin datos	sin datos

2.0yrs

Permanencia media

60.5yo

Promedio de edad

Junta con experiencia: La junta directiva de IMM no se considera experimentada (1.9 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Immutep Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Immutep Limited, Annual General Meeting, Oct 24, 2023

Less than half of directors are independent

Immutep Limited, Annual General Meeting, Nov 23, 2022

Immutep Appoints Frederic Triebel as Executive Director

High number of new and inexperienced directors

Immutep Limited Announces Executive Changes

Recent updates

Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

New minor risk - Profitability

Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761

Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti

Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer

Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023

Immutep Limited Announces Excellent New Clinical Data from the TACTI-002 / KEYNOTE-798 Phase II Trial Evaluating Eftilagimod Alpha

Immutep Limited Announces Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Immutep Limited, Annual General Meeting, Oct 24, 2023

Full year 2023 earnings released: AU$0.045 loss per share (vs AU$0.038 loss in FY 2022)

Immutep Limited Receives Positive Scientific Advice from Committee for Medicinal Products for Human Use of European Medicines Agency for Continued Development of Eftilagimod Alpha

Immutep Limited Announces First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Forecast to breakeven in 2026

Immutep Limited Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

Immutep Limited Announces Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

Immutep Limited Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

No longer forecast to breakeven

First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.019 loss in 1H 2022)

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

Immutep Limited Announces Update on INSIGHT-003 Trial in NSCLC

Immutep Limited Enrolls and Randomised over 50% of the Planned 154 Patients in the Tacti-003 Phase IIB Trial

Immutep Limited Announces the Results of Positive Follow-Up Type C Meeting with the US Food and Drug Administration

Immutep Limited Announces the Successful Scale-Up of the Manufacturing of its Lead Product Candidate Eftilagimod Alpha

Immutep Limited Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

Less than half of directors are independent

Immutep Limited Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

Immutep Limited Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

Immutep Limited Announces the United States Food and Drug Administration (Fda) Has Granted Fast Track Designation to Eftilagimod Alpha

Immutep Limited, Annual General Meeting, Nov 23, 2022

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Appoints Frederic Triebel as Executive Director

Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

No longer forecast to breakeven

Immutep Limited Grants Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor

Immutep Limited Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC

Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates, eftilagimod alpha and IMP76 for the Quarter Ended 30 June 2022

Forecast to breakeven in 2025

Immutep Limited Reports Positive Overall Response Rate in Its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers

High number of new and inexperienced directors

Immutep Limited Announces Executive Changes

Immutep Limited Presents New and Significant Data from the AIPAC Study

Immutep Limited Provides Update on the Ongoing Development of Its Product Candidates, Eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2022

Immutep’S Efti in Combination with Msd’S Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2Nd Line Metastatic Lung Cancer Patients

Immutep Limited Announces New Interim Data in 2nd Line Metastatic NSCLC from Its Phase II TACTI-002 Trial

High number of new directors

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Immutep Limited Appoints Lucy Turnbull as Non-Executive Director

Immutep Limited to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022

Immutep Limited to Present New Data from the Phase II TACTI-002 Study of Efti At ESMO's European Lung Cancer Congress 2022

Immutep Limited Announces Demise of Grant Chamberlain, Non-Executive Director

Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates, Eftilagimod Alpha

No longer forecast to breakeven

Immutep Limited Reports Good Safety from First Five Patients in the INSIGHT-003 study

Immutep to Present Final Overall Survival Data from Phase IIb AIPAC as a Late Breaking Poster Presentation At SITC 2021

Forecast to breakeven in 2024

Full year 2021 earnings released: AU$0.05 loss per share (vs AU$0.034 loss in FY 2020)

Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates

Immutep Receives FDA and IRB Approval in the US for Phase IIb TACTI-003 Trial in HNSCC

Forecast to breakeven in 2024

Immutep Limited Signs Agreement to Commence New Phase I Trial, Called Insight-003, to Evaluate the Combination of Lead Product Candidate Eftilagimod Alpha

Immutep Limited Reveals a New anti-LAG-3 Research Program

Immutep Limited Reports Positive Data from Its Tacti-002 Phase Ii Study of Lag-3 Therapy, Efti, At Asco 2021